To date limited information about cefiderocol use is provided by real life studies. Our aim is to evaluate characteristics and outcome of patients with Gram-negative infections with limited therapeutic options treated with cefiderocol in combination or monotherapy.

Cefiderocol use in Gram negative infections with limited therapeutic options: Is combination therapy the key?

Corcione, Silvia;De Benedetto, Ilaria;Pinna, Simone Mornese;Vita, Davide;Lupia, Tommaso;Montrucchio, Giorgia;Brazzi, Luca;De Rosa, Francesco Giuseppe
2022

Abstract

To date limited information about cefiderocol use is provided by real life studies. Our aim is to evaluate characteristics and outcome of patients with Gram-negative infections with limited therapeutic options treated with cefiderocol in combination or monotherapy.
15
9
975
979
Acinetobacter baumannii; Cefiderocol; Combination therapy; Gram negative bacteria; VAP
Corcione, Silvia; De Benedetto, Ilaria; Pinna, Simone Mornese; Vita, Davide; Lupia, Tommaso; Montrucchio, Giorgia; Brazzi, Luca; De Rosa, Francesco Giuseppe
File in questo prodotto:
File Dimensione Formato  
211 - 2022 Cefiderocol use - Corcione.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 384.49 kB
Formato Adobe PDF
384.49 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/1872678
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact